Active Biotech AB Interim Report January - March 2014
LUND, Sweden, April 24, 2014 (GLOBE NEWSWIRE) --
* On January 24, the laquinimod (Nerventra®) market application received a negative opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Help employers find you! Check out all the jobs and post your resume.